Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Metadata lists "Phio Pharmaceuticals Corp.", but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2017
Event: Entry into a Material Definitive Agreement (Equity Line of Credit) and Unregistered Sales of Equity Securities.
Key Financial Metrics and Transaction Details
- Facility Size: Up to $15,000,000 in common stock sales.
- Counterparty: Lincoln Park Capital Fund, LLC (LPC).
- Commitment Fee: Issuance of 450,000 shares of Common Stock (no cash proceeds received).
- Ownership Limit: LPC cannot beneficially own more than 9.99% of the Common Stock.
- Term: 30-month period commencing upon SEC registration statement effectiveness.
- Use of Proceeds: Working capital and general corporate purposes.
Note: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes and Transaction Mechanics
The Company entered into a Purchase Agreement and Registration Rights Agreement with LPC. Key mechanics include:
- Discretionary Sales: The Company has the sole discretion to direct LPC to purchase shares, subject to a one-business-day waiting period between purchases.
- Purchase Price: Based on market prices at the time of purchase as defined in the agreement.
- Volume Limits:
- Standard: Up to 150,000 shares per business day.
- Accelerated/Additional: Up to 500,000 shares per day if closing sale prices meet certain thresholds, capped at $1,000,000 in proceeds per date.
- Termination: The Company may terminate the agreement at any time without cost or penalty. LPC cannot terminate during an "event of default" (outside LPC's control), though sales are paused until cured.
Guidance, Outlook, and Risks
- Outlook: Actual sales depend on market conditions, trading price, and the Company's funding determinations. No specific sales volume or timing is guaranteed.
- Risks:
- Dilution: Issuance of Commitment Shares and potential future sales will dilute existing shareholders.
- Market Dependency: Proceeds are contingent on the Company's decision to sell and market price thresholds.
- Default Events: Sales are suspended during events of default, which are defined as outside the investor's control.
- Unusual Items: The transaction involves an upfront equity commitment fee (450,000 shares) with no immediate cash inflow.
Investor Verification Checklist
- Verify the current trading price of RXi Pharmaceuticals common stock to assess potential dilution impact.
- Review the full text of the Purchase Agreement (Exhibit 10.1) for specific price thresholds and "event of default" definitions.
- Confirm the status of the SEC registration statement required to activate the 30-month sales window.
- Monitor future filings for actual sales volumes and proceeds generated under this facility.
- Check for any subsequent filings regarding the 9.99% beneficial ownership cap for LPC.